With a focus on patient safety at its core, AIM packs novel features for improved intra-op monitoring, safer outcomes, cost savings, and higher patient satisfaction. 

Risk Mitigation

• Hypoxia is the number one cause of NORA injuries, AIM delivers FiO₂ of 96% and higher.
• Accurate capnography provides early apnea alert, lowering the risk of impending hypoxia.
• Easier airway resuscitation and seamless conversion to general anesthesia may further mitigate patient injuries. 
• May lower the risk of airway fires leading to patient injuries and lawsuits.
• By eliminating bite blocks, AIM facilitates easier placement of EGD and TEE scopes, lowering the risk for soft–palate injuries.

Cost Savings

• General anesthesia is often defaulted for NORA patients even though the procedure may not require general anesthesia, adding $400-600 per case.
  • Longer wake-up time (average 8-12 minutes) leads to prolonged OR occupancy. The cost of OR time is $46.04/minute.
  • Longer recovery room stay (PONV, history of sleep apnea), costs undetermined.
  • Medications – Zemuron $12/vial, Sugammadex $155/vial, Neostigmine $12/vial, Glycopyrolaye $52/vial
  • Supplies – GlideScope $15/blade, LMA $15, breathing circuit $8, suction catheter $4, temperature probe $4, bair-hugger, $20.
• Upon the discretion of the team providing patient care, sedation may be considered with general anesthesia as a backup.

Improved Patient Satisfaction

• Patients report higher satisfaction with sedation versus general anesthesia. 
• Patient satisfaction scores are tied to Medicare reimbursement and malpractice suits.

Reduced Inventory of Multiple Alternative Devices

• Eliminating the need for bite-blocks and awake fiberoptic intubation (pink airways) could lower hospitals’ logistical challenges dealing with multiple vendors, stocking multiple devices, product availability, and price changes.